No DMF deficiency letter received from the office of USFDA for multiple ANDAs

Wanbury Limited recently received "No DMF deficiency letter" from the office of USFDA (US Food and Drug Administration) for multiple ANDAs (Abbreviated New Drug Applications) with Metformin HCl API source of Wanbury for different formulations.

As previously informed, Wanbury expanded business opportunities in South Korea for one more API by filing the DMF. Wanbury is committed for supply of best APIs to the new market for well-being of human being.

Shares of Wanbury Limited was last trading in BSE at Rs. 298.40 as compared to the previous close of Rs. 306.20. The total number of shares traded during the day was 22416 in over 770 trades.

The stock hit an intraday high of Rs. 317.05 and intraday low of 296.40. The net turnover during the day was Rs. 6809151.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Pharmaceuticals